Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Zhiling Yan

Showing results (91-100 of 118) with videos related to

Pageof 12
Sort By:
Journal of Translational Medicine|November 17, 2018
Platycodin D inhibits platelet function and thrombus formation through inducing internalization of platelet glycoprotein receptorsQi Luo, Guangyu Wei, Xiaoqing Wu, et al.
Frontiers in Oncology|July 1, 2021
An Analysis of Cardiac Disorders Associated With Chimeric Antigen Receptor T Cell Therapy in 126 Patients: A Single-Centre Retrospective StudyKunming Qi, Zhiling Yan, Hai Cheng, et al.
BMC Medicine|June 13, 2026
Late phase transfusion after CAR T therapy is associated with persistent hematotoxicity and non-relapse mortality in multiple myeloma: a post hoc analysisFan Xia, Bin Lv, Xinyi Li, et al.
Frontiers in Immunology|May 8, 2023
A combination of pre-infusion serum ferritin, CRP and IL-6 predicts outcome in relapsed/refractory multiple myeloma patients treated with CAR-T cellsYang Liu, Xingxing Jie, Li Nian, et al.
Transplantation and Cellular Therapy|March 30, 2021
Efficacy and Safety of Chimeric Antigen Receptor T-Cell Therapy for Relapsed/Refractory Immunoglobulin D Multiple MyelomaWei Chen, Ying Wang, Kunming Qi, et al.
Frontiers in Immunology|May 2, 2025
The impact of antibiotic use on outcomes of relapsed/refractory multiple myeloma patients treated with CAR-T therapyLingling Yin, Bin Lv, Jiao Ge, et al.
Leukemia|June 29, 2020
Safety and efficacy of chimeric antigen receptor (CAR)-T-cell therapy in persons with advanced B-cell cancers and hepatitis B virus-infectionYing Wang, Yang Liu, Xu Tan, et al.
Cytotherapy|March 12, 2023
Associations of granulocyte colony-stimulating factor with toxicities and efficacy of chimeric antigen receptor T-cell therapy in relapsed or refractory multiple myelomaSha Ma, Hujun Li, Dian Zhou, et al.
The Lancet. Haematology|August 6, 2019
A combination of humanised anti-CD19 and anti-BCMA CAR T cells in patients with relapsed or refractory multiple myeloma: a single-arm, phase 2 trialZhiling Yan, Jiang Cao, Hai Cheng, et al.
Clinical and Experimental Medicine|September 4, 2024
Enhanced platelet function through CAR-T cell therapy in relapsed/refractory multiple myelomaRuixue Ma, Qi Zhang, Yang Liu, et al.
Pageof 12

Showing results (91-100 of 118) with videos related to

Sort By:
Pageof 12
Journal of Translational Medicine|November 17, 2018
Platycodin D inhibits platelet function and thrombus formation through inducing internalization of platelet glycoprotein receptorsQi Luo, Guangyu Wei, Xiaoqing Wu, et al.
Frontiers in Oncology|July 1, 2021
An Analysis of Cardiac Disorders Associated With Chimeric Antigen Receptor T Cell Therapy in 126 Patients: A Single-Centre Retrospective StudyKunming Qi, Zhiling Yan, Hai Cheng, et al.
BMC Medicine|June 13, 2026
Late phase transfusion after CAR T therapy is associated with persistent hematotoxicity and non-relapse mortality in multiple myeloma: a post hoc analysisFan Xia, Bin Lv, Xinyi Li, et al.
Frontiers in Immunology|May 8, 2023
A combination of pre-infusion serum ferritin, CRP and IL-6 predicts outcome in relapsed/refractory multiple myeloma patients treated with CAR-T cellsYang Liu, Xingxing Jie, Li Nian, et al.
Transplantation and Cellular Therapy|March 30, 2021
Efficacy and Safety of Chimeric Antigen Receptor T-Cell Therapy for Relapsed/Refractory Immunoglobulin D Multiple MyelomaWei Chen, Ying Wang, Kunming Qi, et al.
Frontiers in Immunology|May 2, 2025
The impact of antibiotic use on outcomes of relapsed/refractory multiple myeloma patients treated with CAR-T therapyLingling Yin, Bin Lv, Jiao Ge, et al.
Leukemia|June 29, 2020
Safety and efficacy of chimeric antigen receptor (CAR)-T-cell therapy in persons with advanced B-cell cancers and hepatitis B virus-infectionYing Wang, Yang Liu, Xu Tan, et al.
Cytotherapy|March 12, 2023
Associations of granulocyte colony-stimulating factor with toxicities and efficacy of chimeric antigen receptor T-cell therapy in relapsed or refractory multiple myelomaSha Ma, Hujun Li, Dian Zhou, et al.
The Lancet. Haematology|August 6, 2019
A combination of humanised anti-CD19 and anti-BCMA CAR T cells in patients with relapsed or refractory multiple myeloma: a single-arm, phase 2 trialZhiling Yan, Jiang Cao, Hai Cheng, et al.
Clinical and Experimental Medicine|September 4, 2024
Enhanced platelet function through CAR-T cell therapy in relapsed/refractory multiple myelomaRuixue Ma, Qi Zhang, Yang Liu, et al.
Pageof 12